Crossmark

Pathophysiology and treatment of cardiac amyloidosis

Crossref DOI link: https://doi.org/10.1038/nrcardio.2014.165

Published Online: 2014-10-14

Published Print: 2015-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gertz, Morie A.

Dispenzieri, Angela

Sher, Taimur
License Information

Text and Data Mining valid from 2014-10-14
More Information

Article History

First Online: 14 October 2014

Competing interests

: M.A.G. declares that he has received honoraria from Celgene, ISIS, Millennium, Neotope, Novartis, and Onyx. A.D. declares that she has received research funding from Celgene, Janssen, Millennium, and Pfizer. T.S. declares no competing interests.